ðóññêèé   english

Center for Immunotherapy

Novosibirsk — Kaliningrad — Moscow — Irkutsk


In 1995 a scientific research group specializing in the development of medical cellular technologies was established at the Institute of Clinical Immunology of Russian Academy of Medical Sciences. Subsequently, this group became a Laboratory of Cellular Biotechnology, which laid foundation for the Center for Immunotherapy & Ñellular Technologies (CICT). At present, CICT is an informal medical association devoted to the introduction of new immunotherapeutic technologies into clinical practice.


A xenogeneic (murine) polyantigenic cell cancer vaccine (Xenovac) has been developed and clinically tested in CICT. Xenovac consists of murine melanoma and carcinoma antigens. Structural differences of xenogeneic tumor-associated antigens from their human counterparts make these antigens highly immunogenic and capable of stimulating antitumor immune responses in patients with not only early, but also the advanced cancer, by breaking natural immune tolerance to self tumor-associated antigens. In addition, dendritic cell vaccinations with xenogeneic differentiation antigens were found to augment antitumor immune responses. The available data suggest that xenogeneic cancer vaccines (XVT) could be beneficial for treatment of patients with melanoma, renal cancer, colorectal cancer, gastric cancer, lung cancer, prostate cancer, astrocytoma, and breast cancer.


T-cell autoimmunotherapy (autologous T cell vaccination) is aimed at stimulating immune responses directed selectively against pathogenic autoimmune T lymphocytes. The available data indicates that T-cell autoimmunotherapy can be beneficial for the treatment of patients with multiple sclerosis and rheumatoid arthritis. A modified T-cell vaccination protocol could prove to be useful for treatment of ankylosing spondylitis (bechterew’s disease), psoriasis, as well as other autoimmune diseases with unknown etiologies.


Modified T-cell autoimmunotherapy could be useful for treatment of bronchial asthma, urticaria, angioedema, and other allergic diseases with polyantigenic etiology.


Dendritic cell vaccination is a new approach to a personalized treatment of chronic infectious diseases. The dendritic cell-based technology could be efficient to treat chronic virus hepatitis C and B.


Immunotherapeutic regenerative technologies are aimed at actively implicating immune endothelial and stem cells in regenerative processes, and could be of use in treating spinal cord injury, acute brain injury and their long-term consequences, stroke, cerebral palsy, consequences of neuroinfection, cirrhosis, osteomyelitis, arthrosis, and critical limb ischemia.

More information:

Ñell transplantation for severe neurological disorders
Xenogeneic vaccine therapy in cancer treatment
Xenovaccinotherapy for melanoma
Xenovaccinotherapy for colorectal cancer
Xenovaccinotherapy for Cancer
Transplantation treatment of spinal cord injury patients
T-cell autoimmunotherapy (t-cell vaccination) for immune disorders
Induction of Antiidiotypic Immune Response with Autologous T-cell vaccine in Patients with Multiple Sclerosis
Immunological and Clinical Aspects of Cell Therapy in the Treatment of Aftereffects of Craniocerebral Injury
Immune responses induced by T-cell vaccination in patients with rheumatoid arthritis
Clinical application of regenerative cell transplantations
Characterization of Immunogenic Properties of Polyclonal T Cell Vaccine Intended for the Treatment of Rheumatoid Arthritis
Cell transplantation therapy in reanimating severely head-injured patients
Cell Therapy of Comatose States
Cell Therapy of Cerebral Palsy
Cell Therapy of Brain Stroke

to top